MARKET

SNY

SNY

Sanofi FR
NASDAQ
52.40
-0.70
-1.32%
After Hours: 52.27 -0.13 -0.25% 18:47 07/26 EDT
OPEN
52.67
PREV CLOSE
53.10
HIGH
52.85
LOW
52.37
VOLUME
1.99M
TURNOVER
0
52 WEEK HIGH
55.72
52 WEEK LOW
40.90
MARKET CAP
132.55B
P/E (TTM)
28.98
1D
5D
1M
3M
1Y
5Y
1D
Sanofi Is Maintained at Buy by Argus Research
Dow Jones · 6h ago
Sanofi Price Target Raised to $60.00/Share From $55.00 by Argus Research
Dow Jones · 6h ago
Argus Research Maintains Buy on Sanofi, Raises Price Target to $60
Benzinga · 6h ago
FLUZONE® HIGH-DOSE QUADRIVALENT VACCINE REMAINS PREFERENTIALLY RECOMMENDED TO PROTECT ADULTS 65 YEARS OF AGE AND OLDER AGAINST INFLUENZA
Reuters · 10h ago
Dodge & Cox Stock Fund Q2 2024 Shareholder Letter
Seeking Alpha · 11h ago
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
NASDAQ · 11h ago
DZ BANK AG Remains a Hold on Sanofi (SNYNF)
TipRanks · 11h ago
Sanofi ending development of mid-stage dwarfism therapy
Sanofi ending development of mid-stage dwarfism therapy. French pharma will also end development of riliprubart in rare autoimmune disorder cold agglutinin disease. Sanofi is currently in phase 2 to treat achondroplasia, the genetic disorder that causes dwarfism.
Seeking Alpha · 1d ago
More
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Webull offers Sanofi SA (ADR) stock information, including NASDAQ: SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.